Drugs / BCG SSI
BCG SSI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable2 trials | ||||||
| — | NCT02380508 | Feb 2015 → Nov 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| — | NCT02088892 | Mar 2014 → Jan 2015 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT02420444 Background | Jan 2011 → May 2012 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 3 | NCT03947138 Comparator | Aug 2019 → Jun 2022 | tuberculosis | Green Cross Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02504203 Comparator | Nov 2015 → Jun 2021 | — | Bandim Health Project | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03947138 ↗ |
| Known as | Bacille Calmette-Guérin Statens Serum Institute (BCG SSI) | “Bacille Calmette-Guérin Statens Serum Institute (BCG SSI)” NCT02380508 ↗1“Bacille Calmette-Guérin Statens Serum Institute (BCG SSI)” NCT02088892 ↗ |
| Known as | BCG-Denmark 1331 (Statens Serum Institute) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02504203 ↗ |
| Modality | Vaccine | “BCG vaccine” NCT02088892 ↗ |
| Route | Other | “by intradermal injection in the left deltoid region” NCT02504203 ↗ |